Spots Global Cancer Trial Database for Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

Official Title: Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

Study ID: NCT04922307

Conditions

Kidney Cancer

Interventions

Blood Sparing Protocol

Standard Blood Replacement

Study Description

Brief Summary: The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.

Detailed Description: The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT) is a randomized study to investigate blood sparing using autologous normovolemic hemodilution (ANH) or cell salvage at the time of nephrectomy for locally advanced kidney cancer after assessing inclusion criteria patients will be randomized to undergo standard blood management including the possibility of allogenic transfusion vs autologous blood transfusion. There are multiple ways patients can receive allogenic or autologous blood, including veno-venous bypass or cardiopulmonary bypass (typically reserved for patients with a thrombus above the level of the hepatic veins or entering the heart).